MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

InflaRx NV

Uždarymo kaina

1.01 -1.94

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.99

Max

1.06

Pagrindiniai rodikliai

By Trading Economics

Pajamos

12M

-5.1M

Pardavimai

-124K

-423

Pelnas, tenkantis vienai akcijai

-0.08

Pelno marža

1,208,456.738

EBITDA

12M

-5M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+651.96% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

13M

95M

Ankstesnė atidarymo kaina

2.95

Ankstesnė uždarymo kaina

1.01

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

InflaRx NV Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-31 22:45; UTC

Svarbiausios naujienos

Intel's New CEO Plots Turnaround; 'We Need to Improve'

2025-03-31 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise After Monday's Selloff -- Market Talk

2025-03-31 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Tower Shares Ease After Bain Capital Exit -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-03-31 22:33; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

2025-03-31 22:28; UTC

Uždarbis

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke Swings to Loss for 2024 >000002.SZ

2025-03-31 21:47; UTC

Svarbiausios naujienos

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

2025-03-31 21:44; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

2025-03-31 21:21; UTC

Rinkos pokalbiai

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

2025-03-31 21:18; UTC

Svarbiausios naujienos

Copper Is 2025's Hottest Commodity -- Update

2025-03-31 21:09; UTC

Svarbiausios naujienos

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

2025-03-31 21:02; UTC

Uždarbis

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

2025-03-31 21:01; UTC

Uždarbis

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

2025-03-31 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-03-31 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-03-31 20:37; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

2025-03-31 20:17; UTC

Svarbiausios naujienos

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

2025-03-31 20:13; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

2025-03-31 20:03; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

2025-03-31 19:09; UTC

Rinkos pokalbiai

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

2025-03-31 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains With Help From Weather -- Market Talk

2025-03-31 18:54; UTC

Rinkos pokalbiai

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

2025-03-31 18:40; UTC

Rinkos pokalbiai

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

2025-03-31 18:34; UTC

Rinkos pokalbiai

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

2025-03-31 18:28; UTC

Rinkos pokalbiai

Gold Climbs to Close Out Quarter -- Market Talk

2025-03-31 18:03; UTC

Svarbiausios naujienos

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Akcijų palyginimas

Kainos pokytis

InflaRx NV Prognozė

Kainos tikslas

By TipRanks

651.96% į viršų

12 mėnesių prognozė

Vidutinis 7.67 USD  651.96%

Aukščiausias 10 USD

Žemiausias 5 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines InflaRx NV kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 1.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.